Classes of Therapeutics to Amplify the Immune Response

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2021 Nov 17

PMID 34787761

Authors

Yang Hu

Mark E Burkard

Affiliations

Soon will be listed here.

Abstract

Purpose: Conventional chemotherapies are a mainstay for metastatic breast cancers, though durable response is rare. Immunotherapies promise long-term responses thorough immune activation but have been underwhelming in breast cancer relative to other cancer types. Here, we review the mechanisms of existing strategies including chemotherapies and how they may cause breast cancers to become immunogenic to identify potential biomarkers for combinations of conventional and immunotherapies.

Conclusion: Mechanistic considerations should inform biomarker development and patient selection for therapeutic combinations of drugs to combine with immune-checkpoint inhibitors.

References

Vikas P, Borcherding N, Zhang W . The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res. 2018; 10:6823-6833. PMC: 6292225. DOI: 10.2147/CMAR.S185176. View

Anderson K, Stromnes I, Greenberg P . Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 2017; 31(3):311-325. PMC: 5423788. DOI: 10.1016/j.ccell.2017.02.008. View

Gustafson C, Jadhav R, Cao W, Qi Q, Pegram M, Tian L . Immune cell repertoires in breast cancer patients after adjuvant chemotherapy. JCI Insight. 2020; 5(4). PMC: 7101137. DOI: 10.1172/jci.insight.134569. View

Morrison R, Schleicher S, Sun Y, Niermann K, Kim S, Spratt D . Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2010; 2011:941876. PMC: 2958340. DOI: 10.1155/2011/941876. View

Fu J, Kanne D, Leong M, Glickman L, McWhirter S, Lemmens E . STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015; 7(283):283ra52. PMC: 4504692. DOI: 10.1126/scitranslmed.aaa4306. View

Jiang M, Gu D, Dai J, Huang Q, Tian L . Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation. Trends Cancer. 2020; 6(5):419-431. DOI: 10.1016/j.trecan.2020.01.018. View

Sun S . Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl Oncol. 2020; 13(12):100847. PMC: 7451686. DOI: 10.1016/j.tranon.2020.100847. View

Emens L . Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2017; 24(3):511-520. PMC: 5796849. DOI: 10.1158/1078-0432.CCR-16-3001. View

Benedetti R, DellAversana C, Giorgio C, Astorri R, Altucci L . Breast Cancer Vaccines: New Insights. Front Endocrinol (Lausanne). 2017; 8:270. PMC: 5645504. DOI: 10.3389/fendo.2017.00270. View

10.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G . Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019; 20(3):371-382. DOI: 10.1016/S1470-2045(18)30812-X. View

11.

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Buque Martinez A . Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020; 8(1). PMC: 7064135. DOI: 10.1136/jitc-2019-000337. View

12.

Yang H, Rudge D, Koos J, Vaidialingam B, Yang H, Pavletich N . mTOR kinase structure, mechanism and regulation. Nature. 2013; 497(7448):217-23. PMC: 4512754. DOI: 10.1038/nature12122. View

13.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I . Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015; 4(4):e1008866. PMC: 4485780. DOI: 10.1080/2162402X.2015.1008866. View

14.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

15.

Baselga J, Albanell J . Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 2001; 12 Suppl 1:S35-41. DOI: 10.1093/annonc/12.suppl_1.s35. View

16.

Morimoto Y, Kishida T, Kotani S, Takayama K, Mazda O . Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. Biochem Biophys Res Commun. 2018; 507(1-4):330-336. DOI: 10.1016/j.bbrc.2018.11.035. View

17.

Wang Z, Till B, Gao Q . Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017; 6(7):e1331807. PMC: 5543863. DOI: 10.1080/2162402X.2017.1331807. View

18.

Kalli K, Block M, Kasi P, Erskine C, Hobday T, Dietz A . Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res. 2018; 24(13):3014-3025. PMC: 6030477. DOI: 10.1158/1078-0432.CCR-17-2499. View

19.

Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A . A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 2016; 65(2):151-60. PMC: 11028889. DOI: 10.1007/s00262-015-1781-6. View

20.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View